TLDR
- ARK bought 188,665 CoreWeave shares on October 14 after the stock fell 15.5%.
- CoreWeave is down 53% over the past year as debt worries grow.
- ARK sold 31,432 Palantir shares after the stock gained more than 60% since August.
- ARK also sold Personal Genome Diagnostics, 10X Genomics, Toast and Shopify shares.
- Wall Street rates both CoreWeave and Palantir a Moderate Buy.
Cathie Wood’s ARK Invest added to its CoreWeave position on Wednesday, October 14, 2026, even as the stock sank. The firm also sold shares of Palantir Technologies and Personal Genome Diagnostics.
CoreWeave, Inc. Class A Common Stock, CRWV
ARK bought 188,665 CoreWeave shares across its funds. The daily trade report valued the purchase at $14,680,023, while another report put it near $12.4 million.
CoreWeave fell 15.5% in regular trading. The stock is down 53% over the past year, and concerns about mounting financial obligations have weighed on investor confidence.
Why CoreWeave Shares Fell
Investors are focused on the company’s debt. Its $1.25 billion in unsecured bonds due in 2032 recently reached a yield of 15%.
Venture capitalist Chamath Palihapitiya warned about possible trouble in AI infrastructure financing. Elon Musk replied with one word: “Yikes.”
CoreWeave had about $52 billion in debt and lease obligations as of June. The company is now looking at other ways to raise money.
The Financial Times reported that CoreWeave is exploring financing from life insurance companies. It wants investment-grade financing backed by its computing infrastructure.
Hotter-than-expected September inflation data also hurt the market on Wednesday. It raised concerns about more Federal Reserve interest rate hikes.
Wall Street rates CoreWeave a Moderate Buy. The average price target is $143.96, about 119% above Wednesday’s close.
ARK’s Other Trades
ARK sold 31,432 Palantir shares, valued at $6,558,915 in the trade report. Palantir fell 3.7% on Wednesday after rising more than 60% since early August.
The company reported second-quarter revenue of $1.94 billion, up 93% from a year earlier. Barclays started coverage at Overweight with a $265 target, and Goldman Sachs upgraded the stock to Buy.
Palantir trades at 163.9 times trailing earnings. Its average price target of $210.67 points to a 5% gain.
ARK sold 693,049 shares of Personal Genome Diagnostics for $10,984,826. It also sold 113,555 shares of 10X Genomics for $8,152,113.
The firm sold Toast shares for $10,424,540 and Shopify shares for $4,519,794. It bought 9,577 Meta Platforms shares for $7,302,462.
ARK also bought 44,689 shares of Cerebras Systems for $6,662,683 and 110,037 shares of Freenome for $1,390,867. It added 500,457 Kodiak AI shares and 459 Scribe Therapeutics shares.
CoreWeave shares slipped another 3.5% in after-hours trading on Wednesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
